Recent Finacing
Recent Raise
Precirix develops camelid single‑domain antibody–based radiopharmaceuticals for theranostic imaging and therapy, advancing CAM‑H2 for HER2‑positive metastatic breast and gastric cancer alongside preclinical candidates and platform development.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
